174 related articles for article (PubMed ID: 21306815)
41. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
[TBL] [Abstract][Full Text] [Related]
42. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure?
Lassnigg A; Schmid ER; Hiesmayr M; Falk C; Druml W; Bauer P; Schmidlin D
Crit Care Med; 2008 Apr; 36(4):1129-37. PubMed ID: 18379238
[TBL] [Abstract][Full Text] [Related]
43. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
44. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
Bristow RE; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1070-6. PubMed ID: 16875720
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-6 plays a protective role in development of cisplatin-induced acute renal failure through upregulation of anti-oxidative stress factors.
Mitazaki S; Honma S; Suto M; Kato N; Hiraiwa K; Yoshida M; Abe S
Life Sci; 2011 Jun; 88(25-26):1142-8. PubMed ID: 21570986
[TBL] [Abstract][Full Text] [Related]
46. Serum creatinine and cholesterol levels of testicular cancer patients in long-term follow up.
Hisamatsu E; Kawai K; Hinotsu S; Miyanaga N; Shimazui T; Akaza H
Int J Urol; 2005 Aug; 12(8):751-6. PubMed ID: 16174050
[TBL] [Abstract][Full Text] [Related]
47. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
[TBL] [Abstract][Full Text] [Related]
48. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
49. Irreversible renal failure after intraperitoneal cisplatin administration. A case report.
Gouge SF; Tietjen DP; Moore J
J Reprod Med; 1989 Nov; 34(11):931-3. PubMed ID: 2585396
[TBL] [Abstract][Full Text] [Related]
50. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
[TBL] [Abstract][Full Text] [Related]
51. [Glutamin concentrations in patients treated with cisplatin have a predicting value of renal failure development].
Cobo M; Martín Gómez MA; Frutos MA; Benavides M
Nefrologia; 2007; 27(1):23-9. PubMed ID: 17402876
[TBL] [Abstract][Full Text] [Related]
52. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
Yoshida T; Niho S; Toda M; Goto K; Yoh K; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Apr; 44(4):346-54. PubMed ID: 24503028
[TBL] [Abstract][Full Text] [Related]
53. KDIGO (Kidney Disease: Improving Global Outcomes) criteria could be a useful outcome predictor of cisplatin-induced acute kidney injury.
Mizuno T; Sato W; Ishikawa K; Shinjo H; Miyagawa Y; Noda Y; Imai E; Yamada K
Oncology; 2012; 82(6):354-9. PubMed ID: 22722365
[TBL] [Abstract][Full Text] [Related]
54. Comparison of perioperative morbidity in patients with ovarian malignancy undergoing radical cancer surgery with or without prior chemotherapy.
Kathirvel S; Saxena A; Trikha A; Saxena A; Saxena R; Ahuja RK
Indian J Med Res; 1999 May; 109():175-81. PubMed ID: 10643142
[TBL] [Abstract][Full Text] [Related]
55. Lower Blood Pressure-Induced Renal Hypoperfusion Promotes Cisplatin-Induced Nephrotoxicity.
Mizuno T; Hayashi T; Shimabukuro Y; Murase M; Hayashi H; Ishikawa K; Takahashi K; Yuzawa Y; Yamada S; Nagamatsu T
Oncology; 2016; 90(6):313-20. PubMed ID: 27225867
[TBL] [Abstract][Full Text] [Related]
56. Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice.
Solanki MH; Chatterjee PK; Xue X; Gupta M; Rosales I; Yeboah MM; Kohn N; Metz CN
Am J Physiol Renal Physiol; 2015 Jul; 309(1):F35-47. PubMed ID: 25947343
[TBL] [Abstract][Full Text] [Related]
57. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
[TBL] [Abstract][Full Text] [Related]
58. Normobaric hyperoxia preconditioning ameliorates cisplatin nephrotoxicity.
Saadat A; Shariat Maghani SS; Rostami Z; Davoudi A; Davoudi F; Shafie A; Eynollahi B
Ren Fail; 2014 Feb; 36(1):5-8. PubMed ID: 24059271
[TBL] [Abstract][Full Text] [Related]
59. Prevention of cis-platinum nephrotoxicity in a high-risk patient.
Donadio C; Lucchesi A; Gadducci A
Ren Fail; 1996 Jul; 18(4):691-5. PubMed ID: 8875699
[TBL] [Abstract][Full Text] [Related]
60. Epinephrine enhances penetration and anti-cancer activity of local cisplatin on rat sub-cutaneous and peritoneal tumors.
Duvillard C; Benoit L; Moretto P; Beltramo JL; Brunet-Lecomte P; Correia M; Sergent C; Chauffert B
Int J Cancer; 1999 May; 81(5):779-84. PubMed ID: 10328233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
